Abstract
Gastric cancer remains a leading cause of cancer-related death in the world. FGF receptor 2 (FGFR2) is preferentially amplified and overexpressed in the diffuse type of gastric cancer. This review evaluates the expression and function of FGFR2 in gastric cancer, and analyzes the use of its inhibitors for gastric cancer therapy. This review also discusses the limitations of FGFR2-based therapy, and envisages future developments toward the clinical applications of FGFR2.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Drug Resistance, Neoplasm
-
Humans
-
Molecular Targeted Therapy* / adverse effects
-
Protein Kinase Inhibitors / adverse effects
-
Protein Kinase Inhibitors / therapeutic use*
-
Receptor, Fibroblast Growth Factor, Type 2 / antagonists & inhibitors*
-
Receptor, Fibroblast Growth Factor, Type 2 / metabolism
-
Signal Transduction / drug effects
-
Stomach Neoplasms / drug therapy*
-
Stomach Neoplasms / enzymology
-
Stomach Neoplasms / pathology
Substances
-
Antineoplastic Agents
-
Protein Kinase Inhibitors
-
FGFR2 protein, human
-
Receptor, Fibroblast Growth Factor, Type 2